This article refers to:
Edwards T, Patel NU, Blake A. Insights into future therapeutics for atopic dermatitis. 2018 Feb;19(3):265–278.
http://dx.doi.org/10.1080/14656566.2018.1430140
When the above article was published, the p value in the AD-301 study was incorrect. This has now been corrected to:
In additional phase 3 studies (AD-301: NCT02118766; AD-302: NCT02118792), crisaborole-treated patients achieved investigator’s static global assessment (ISGA) score success of clear/almost clear (2- or greater-grade improvement) more often than the vehicle group (AD-301: 32.8% vs. 25.4%, p = .038; AD-302: 31.4% vs. 18.0%, p < .001) [10].